Avaliação da viabilidade do uso de angiotensina 1-7 através da mesoterapia capilar para o tratamento de alopecia androgenética

Abstract

Androgenetic Alopecia (AGA) is characterized as a hereditary disease, dependent on hormones and marked by an alteration in the hair cycle resulting in minimization of the hair follicle, which brings as a consequence thinner, shorter and less pigmented hair. It is currently understood that its prevalence is associated with age, sex, and ethnicity (CHAVES et al., 2021). Among the Caucasian population, approximately 80% of men can be affected by androgenetic alopecia, a rate that is significantly lower among women, corresponding to 40% to 50% of women over 45 years. Notably, AGA is less prevalent among blacks and Asians (CHAVES et al., 2021), and the complaint most commonly reported by those affected by the disease is thinning hair, resulting in thinning hair and exposed scalp. This study aims to evaluate the feasibility of treating androgenetic alopecia using angiotensin 1-7 by means of hair mesotherapy. To this end, it was proposed to carry out a literature review on the subject, based on a qualitative bibliographic research with an exploratory purpose. Angiotensin 1-7 is characterized as a heptapeptide of sequence "Asp-Arg-Val-Tyr-Ile-His-Pro" and an important member of the Renin-Angiotensin System, and this peptide can be formed directly by the action of angiotensin II-converting enzyme on Ang I resulting in angiotensin 1-9, which in turn is converted into Angiotensin 1-7 by ACE or by neutral endopeptidase (NEP) (PONTES, 2018).